-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyverna Q1 FY26 net loss narrows to $39.7 million

PUBT·05/12/2026 20:03:40
Listen to the news
Kyverna Q1 FY26 net loss narrows to $39.7 million
  • Kyverna Therapeutics posted a net loss of USD 39.7 million, or USD 0.66 per share, for first-quarter 2026.
  • R&D expense fell to USD 30.1 million from USD 37.43 million a year earlier, while G&A expense rose to USD 11.3 million from USD 9.98 million.
  • Cash, cash equivalents, and marketable securities declined to USD 236.4 million as of March 31, 2026; cash runway forecast remains into 2028.
  • Rolling BLA submission for miv-cel in stiff person syndrome began following FDA alignment that the KYSA-8 single-arm Phase 2 trial can support the filing; completion expected in Q4 2026 with priority review sought under RMAT.
  • Launch preparations for stiff person syndrome continue for 2027, while enrollment advances in the Phase 3 portion of the KYSA-6 registrational trial in generalized myasthenia gravis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121602PRIMZONEFULLFEED9718581) on May 12, 2026, and is solely responsible for the information contained therein.